AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Resmed DRC

38.000

+0.3300.88%

Volume:740.31K

Turnover:28.18M

Market Cap:55.72B

PE:29.49

High:38.320

Open:38.000

Low:37.990

Close:37.670

Loading ...

Overview Company News Filings

PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall

DVA Stock Down in Pre-Market Despite Q4 Earnings Beat, Margins Expand

Here's Why ResMed (RMD) Could be Great Choice for a Bottom Fisher

ResMed Inc. Stock Rises Thursday, Outperforms Market

WST Stock Declines in Pre-Market Despite Q4 Earnings Beat, Margins Down

QuidelOrtho Stock Gains Following Q4 Earnings Beat, Margins Contract

CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise

DexCom (DXCM) To Report Earnings Tomorrow: Here Is What To Expect

3 ASX growth stocks to watch as earnings hit a turning point

4 ASX 300 shares with ex-dividend dates before this week ends

I would invest $500 a month into ASX shares to retire rich

3 ASX 200 shares that have returned more than 17% a year over the last decade

ECL Stock Up in Pre-Market Following Q4 Earnings Beat, Margins Expand

INSP Stock Declines Despite Q4 Earnings Beat, Gross Margin Contracts

MYGN Stock Might Rise on Collaboration With CancerCARE

ResMed Close To Joining Very Elite Stock Group

ResMed Getting Closer To Key Technical Benchmark

Resmed Chief Financial Officer Sells 1,000 Shares

MT Newswires Live

Avantor Stock Declines Despite Q4 Earnings Beat, Margins Expand

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RMD.AU/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RMD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","market":"AU","secType":"STK","nameCN":"Resmed DRC","latestPrice":38,"timestamp":1746684720000,"preClose":37.67,"halted":0,"volume":740310,"delay":0,"nameEN":"Resmed DRC","floatShares":145691036,"shares":1466188140,"eps":1.28845853506169,"marketStatus":"Not Yet Opened","change":0.33,"latestTime":"05-08 16:12:00 AEST","open":38,"high":38.32,"low":37.99,"amount":28177864,"amplitude":0.00876,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.28845853506169,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746748800000},"marketStatusCode":0,"adr":0,"adrRate":1,"exchange":"ASX","adjPreClose":37.67,"dividendRate":0.008096,"openAndCloseTimeList":[[1746662400000,1746684000000]],"volumeRatio":1.0632574333445273,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","floatShares":145691036,"roa":"14.01%","roe":"25.81%","lyrEps":0.976105,"volumeRatio":1.0632574333445273,"shares":1466188140,"dividePrice":0.307668,"high":38.32,"amplitude":0.00876,"preClose":37.67,"low":37.99,"week52Low":26.886,"pbRate":"6.43","psRate":"7.10","week52High":40.57,"institutionHeld":0,"latestPrice":38,"eps":1.28845853506169,"divideRate":0.008096,"volume":740310,"delay":0,"ttmEps":1.28845853506169,"open":38,"prevYearClose":36.608,"prevWeekClose":37.177,"prevMonthClose":36.598,"prevQuarterClose":34.882,"fiveDayClose":36.818,"twentyDayClose":33.386,"sixtyDayClose":37.743},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RMD.AU\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2511761898","title":"PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2511761898","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511761898?lang=en_us&edition=fundamental","pubTime":"2025-02-15 00:04","pubTimestamp":1739549040,"startTime":"0","endTime":"0","summary":"Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 20 cents in fourth-quarter 2024, narrower than the year-ago adjusted loss of 27 cents per share. The adjusted loss per share was in line with the Zacks Consensus Estimate.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The company’s GAAP earnings per share  was a penny in the quarter against the year-ago period’s loss of 31 cents.Full-year adjusted loss per share was 83 cents, narrower than the adjusted loss of $1.11 per share at the end of the comparable 2023 period. However, the figure was wider than the Zacks Consensus Estimate of a loss of 81 cents.PacBio registered revenues of $39.2 million in the fourth quarter, down 32.8% year over year. However, the figure surpassed the Zacks Consensus Estimate by 0.1%.In the Asia-Pacific region, PacBio recorded revenues of $8.9 million, reflecting a 33% decline year over year. The sequential growth in consumab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pacb-stock-down-following-line-160400123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["PACB","RMD.AU","RMD","BSX","CAH"],"gpt_icon":0},{"id":"2511934618","title":"DVA Stock Down in Pre-Market Despite Q4 Earnings Beat, Margins Expand","url":"https://stock-news.laohu8.com/highlight/detail?id=2511934618","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511934618?lang=en_us&edition=fundamental","pubTime":"2025-02-15 00:00","pubTimestamp":1739548800,"startTime":"0","endTime":"0","summary":"DaVita Inc. DVA delivered adjusted earnings per share  of $2.24 in the fourth quarter of 2024, up 19.8% year over year. The figure surpassed the Zacks Consensus Estimate by 1.4%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.GAAP EPS for the quarter was $3.09, reflecting a jump of 90.7% year over year.Full-year 2024 adjusted EPS was $9.68, up 26.2% from the comparable 2023 period. However, the metric lagged the Zacks Consensus Estimate by 0.3%.Per management, the revenue uptick primarily resulted from seasonal impacts  and other normal fluctuations.DaVita generates revenues via two sources — Dialysis patient service revenues and Other revenues.As of Dec. 31, DaVita had approximately 70,400 patients in risk-based integrated care arrangements in its Integrated Kidney Care business, representing $5.5 billion in annualized medical spend. The company also had an additional 11,600 patients in other integrated care arrangements.DaVita exited 2024 with cash and cash equ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dva-stock-down-pre-market-160000636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD.AU","DVA","BSX","CAH","RMD"],"gpt_icon":0},{"id":"2511697636","title":"Here's Why ResMed (RMD) Could be Great Choice for a Bottom Fisher","url":"https://stock-news.laohu8.com/highlight/detail?id=2511697636","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511697636?lang=en_us&edition=fundamental","pubTime":"2025-02-14 22:55","pubTimestamp":1739544908,"startTime":"0","endTime":"0","summary":"Shares of ResMed  have been struggling lately and have lost 7.1% over the past two weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings of this maker of medical products for respiratory disorders is a solid fundamental factor that enhances the prospects of a trend reversal for the stock.What is a Hammer Chart and How to Trade It?If this is not enough, you should note that RMD currently has a Zacks Rank #2 , which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-resmed-rmd-could-145508272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4142","BK4504","LU2177674079.SGD","RMD","BK4082","BK7007","CHH","LU2008162690.USD","BK4585","RMD.AU","BK4548","BK4567","BK7501","BK4588"],"gpt_icon":1},{"id":"2511503448","title":"ResMed Inc. Stock Rises Thursday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2511503448","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511503448?lang=en_us&edition=fundamental","pubTime":"2025-02-14 05:54","pubTimestamp":1739483640,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of ResMed Inc.  advanced 1.44% to $239.48 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 1.04% to 6,115.07 and the Dow Jones Industrial Average  rising 0.77% to 44,711.43.The stock's rise snapped a two-day losing streak.ResMed Inc. closed 8.96% short of its 52-week high of $263.05, which the company achieved on January 30th.Trading volume  remained 175,842 below its 50-day average volume of 872,105.Data source: Dow Jones Market Data, FactSet. Data compiled February 13, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD","RMD.AU"],"gpt_icon":0},{"id":"2511732935","title":"WST Stock Declines in Pre-Market Despite Q4 Earnings Beat, Margins Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2511732935","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511732935?lang=en_us&edition=fundamental","pubTime":"2025-02-13 23:54","pubTimestamp":1739462040,"startTime":"0","endTime":"0","summary":"West Pharmaceutical Services, Inc. WST delivered adjusted earnings per share  of $1.82 in the fourth quarter of 2024, down by a penny year over year. The figure topped the Zacks Consensus Estimate by 4%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustments include expenses related to amortization of acquisition-related intangible assets, among others.GAAP EPS for the quarter was $1.78, reflecting a decline of 2.7% from the year-ago figure.Full-year 2024 EPS was $6.75, down 16.5% from the comparable 2023 period. The metric surpassed the Zacks Consensus Estimate by 1.2%.West Pharmaceutical registered revenues of $748.8 million in the fourth quarter, up 2.3% year over year. The figure surpassed the Zacks Consensus Estimate by 1.3%.Organic net sales, which excludes the impact of acquisitions and/or divestitures, were $756 million during the fourth quarter .On an organic basis, revenues were $620.4 million, up 4.5% year over year.Revenues in the Contract-Man","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wst-stock-declines-pre-market-155400500.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["WST","RMD.AU","BSX","CAH","RMD"],"gpt_icon":0},{"id":"2511520933","title":"QuidelOrtho Stock Gains Following Q4 Earnings Beat, Margins Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2511520933","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511520933?lang=en_us&edition=fundamental","pubTime":"2025-02-13 23:51","pubTimestamp":1739461860,"startTime":"0","endTime":"0","summary":"QuidelOrtho Corporation QDEL delivered adjusted earnings per share  of 63 cents in the fourth quarter of 2024, down 46.2% year over year. The figure, however, topped the Zacks Consensus Estimate by 14.6%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustments include expenses related to the amortization of intangibles, and acquisition and integration costs, among others.GAAP loss per share for the quarter was $2.28 against the year-earlier EPS of 10 cents.Full-year 2024 EPS was $1.85, down 55.2% from the comparable 2023 period. However, the metric surpassed the Zacks Consensus Estimate by 4.5%.QuidelOrtho registered revenues of $707.8 million in the fourth quarter of 2024, which decreased 4.7% year over year on a reported basis and 4.4% at constant exchange rate . However, the figure surpassed the Zacks Consensus Estimate by 0.8%.In the fourth quarter, Respiratory revenues were $143.2 million , while Non-Respiratory revenues were $564.6 million .In the fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quidelortho-stock-gains-following-q4-155100847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAH","RMD","BSX","RMD.AU"],"gpt_icon":0},{"id":"2510330606","title":"CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2510330606","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510330606?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:37","pubTimestamp":1739367420,"startTime":"0","endTime":"0","summary":"CVS Health CorporationCVS posted adjusted earnings per share  of $1.19 in the fourth quarter of 2024, down 43.9% year over year. However, the metric topped the Zacks Consensus Estimate by 33.7%. The adjusted EPS figure considers certain asset amortization costs, loss on assets held for sale and other adjustments.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.On a reported basis, the company’s GAAP earnings were $1.30 per share compared with $1.58 in the prior-year period.For the full year, adjusted earnings were $5.42 per share, down 37.9% from the year-ago period’s levels. It surpassed the Zacks Consensus Estimate by 5.4%.Revenues in the fourth quarter rose 4.2% year over year to $97.71 billion. The top line surpassed the Zacks Consensus Estimate by 0.6%. This year-over-year upside was driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments.Total revenues for 2024 were $372.81 billion, up 4.2% from the year-ago period’s levels. Th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvs-health-stock-q4-earnings-133700513.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RMD.AU","CVS","BIO","RMD","CAH"],"gpt_icon":0},{"id":"2510723953","title":"DexCom (DXCM) To Report Earnings Tomorrow: Here Is What To Expect","url":"https://stock-news.laohu8.com/highlight/detail?id=2510723953","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510723953?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:07","pubTimestamp":1739365668,"startTime":"0","endTime":"0","summary":"Medical device company DexCom  will be reporting earnings tomorrow after the bell. Here’s what investors should know.DexCom met analysts’ revenue expectations last quarter, reporting revenues of $994.2 million, up 2% year on year. It was a mixed quarter for the company, with an impressive beat of analysts’ organic revenue estimates but EPS in line with analysts’ estimates.Is DexCom a buy or sell going into earnings?Read our full analysis here, it’s free.This quarter, analysts are expecting DexCom’s revenue to grow 6.7% year on year to $1.10 billion, slowing from the 26.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.50 per share.Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known  semiconductor stock benefiting from the rise of AI. Click here to a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dexcom-dxcm-report-earnings-tomorrow-130748106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD","RMD.AU","DXCM"],"gpt_icon":0},{"id":"2510534586","title":"3 ASX growth stocks to watch as earnings hit a turning point","url":"https://stock-news.laohu8.com/highlight/detail?id=2510534586","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510534586?lang=en_us&edition=fundamental","pubTime":"2025-02-12 14:02","pubTimestamp":1739340159,"startTime":"0","endTime":"0","summary":"This interview was recorded on Tuesday 11 February 2025.Share markets are at near-highs. The RBA is expected to start cuts next week. There’s change in the air and something that seems like…hope. FNArena’s Rudi Filapek-Vandycknotes that all reporting seasons have their own character and this one spells a significant change compared to the more depressed mood of August 2024. The optimism is back and Filapek-Vandyck points to a few key reasons.“There is a growing confidence now that earnings in Australia have bottomed, and we will see better times ahead. That’s already being reflected in forecasts,” he says.He adds that the prospect of rate cuts supports his optimism and his view that 2025 may be the year that the “60% that haven’t performed over the past two years” finally get going.The two sectors and three stocks to watch this season. “The one telecommunication company that has been put forward as potentially shooting out the lights this year is Superloop and they have been on a tear ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/3-asx-growth-stocks-to-watch-as-earnings-hit-a-turning-point","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/3-asx-growth-stocks-to-watch-as-earnings-hit-a-turning-point","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7094","IDX.AU","TLS.AU","BK7046","HUB.AU","ACL.AU","RHC.AU","BK7042","BK7135","PME.AU","RMD.AU","TPG.AU","BK7113","TLX.AU","CBA.AU","BK7511","XAO.AU","SHL.AU","HLS.AU","BK7054","BK7124","BK7067","BK7007","XJO.AU","BK7509","BK7508","BK7503","XKO.AU","SLC.AU","CSL.AU","INTEU","BK7016","BK7015","MQG.AU","WTC.AU","COH.AU","BK7501"],"gpt_icon":0},{"id":"2510348591","title":"4 ASX 300 shares with ex-dividend dates before this week ends","url":"https://stock-news.laohu8.com/highlight/detail?id=2510348591","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510348591?lang=en_us&edition=fundamental","pubTime":"2025-02-12 12:33","pubTimestamp":1739334783,"startTime":"0","endTime":"0","summary":"Earnings season is accelerating this week, as we hear from ASX 300 shares like Commonwealth Bank of Australia (ASX: CBA), Computershare Ltd (ASX: CPU), and CSL Ltd (ASX: CSL). While all eyes will be o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/12/4-asx-300-shares-with-ex-dividend-dates-before-this-week-ends/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["REIT","BK7007","BK7126","CSL.AU","BK7033","CBA.AU","BK7503","BK7135","BK7501","REIT.AU","SCG.AU","BK7067","BK7511","BK7510","BK7068","DDR.AU","CPU.AU","BK7162","BK7508","ANN.AU","BK7005","BK7157","RMD.AU"],"gpt_icon":0},{"id":"2510363470","title":"I would invest $500 a month into ASX shares to retire rich","url":"https://stock-news.laohu8.com/highlight/detail?id=2510363470","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510363470?lang=en_us&edition=fundamental","pubTime":"2025-02-12 04:15","pubTimestamp":1739304954,"startTime":"0","endTime":"0","summary":"When it comes to retirement, you don't want to end up with too little. The good news is that you could stop this from happening by investing in ASX shares. For example, investing just $500 a month into high-quality ASX shares could be the key to building a million-dollar retirement portfolio. The secret lies in consistency, time, and the power of compound returns. Here's what you need to know: The power of long-term investing The Australian share market has historically delivered an average annual return of around 10%, including dividends. By committing to investing $500 every month and reinvesting the returns, you could amass a substantial sum over time if this trend continues. If you followed this strategy for 30 years, earning a 10% annual return, your portfolio would grow to just over $1 million. This is the magic of compounding—your returns generate more returns, and over time, this snowballs into serious wealth. Which ASX shares?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/12/i-would-invest-500-a-month-into-asx-shares-to-retire-rich/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7016","BK7099","BK7041","BK7155","BK7511","RMD.AU","WES.AU","BK7153","GMG.AU","BK7510","BK7007","BK7501","BK7503","TNE.AU"],"gpt_icon":1},{"id":"2510351847","title":"3 ASX 200 shares that have returned more than 17% a year over the last decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2510351847","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510351847?lang=en_us&edition=fundamental","pubTime":"2025-02-12 01:39","pubTimestamp":1739295540,"startTime":"0","endTime":"0","summary":"Over the past 10 years, theS&P/ASX 200 Index(ASX: XJO) has delivered a return of approximately 9% per annum for investors. While this is a good return, it is short of what has been recorded by Wall St","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/12/3-asx-200-shares-that-have-returned-more-than-17-a-year-over-the-last-decade/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","BK7503","BK7155","BK7007","GMG.AU","XJO.AU","RMD.AU","BK7099","BK7016","BK7510","XRO.AU"],"gpt_icon":0},{"id":"2510635383","title":"ECL Stock Up in Pre-Market Following Q4 Earnings Beat, Margins Expand","url":"https://stock-news.laohu8.com/highlight/detail?id=2510635383","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510635383?lang=en_us&edition=fundamental","pubTime":"2025-02-12 00:42","pubTimestamp":1739292120,"startTime":"0","endTime":"0","summary":"Ecolab Inc. ECL reported fourth-quarter 2024 adjusted earnings per share  of $1.81, up 16.8% year over year. The bottom line exceeded the Zacks Consensus Estimate by 1.1%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.GAAP EPS for the quarter was $1.66, up 17.7% year over year.Full-year 2024 adjusted EPS was $6.65, up 27.6% from the comparable 2023 period. The metric surpassed the Zacks Consensus Estimate by a penny.Revenues grossed $4.01 billion in the reported quarter, up 1.7% year over year. The metric topped the Zacks Consensus Estimate by 0.8%.The Global Institutional & Specialty arm’s fixed currency sales and organic sales were $1.37 billion each, reflecting growth of 5.5% year over year both on a reported and organic basis.The Global Pest Elimination segment’s fixed currency sales of $295.2 million improved 8.2% year over year on a reported basis. Organic sales were $290.7 million, up 6.6% year over year.In the quarter under review, Ecolab’s gross profit ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ecl-stock-pre-market-following-164200552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BSX","RMD.AU","ECL","CAH","RMD"],"gpt_icon":0},{"id":"2510358767","title":"INSP Stock Declines Despite Q4 Earnings Beat, Gross Margin Contracts","url":"https://stock-news.laohu8.com/highlight/detail?id=2510358767","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510358767?lang=en_us&edition=fundamental","pubTime":"2025-02-12 00:23","pubTimestamp":1739290980,"startTime":"0","endTime":"0","summary":"Inspire Medical Systems, Inc. INSP delivered an earnings per share  of $1.15 in fourth-quarter 2024, up 134.7% from the year-ago period’s EPS of 49 cents. The metric surpassed the Zacks Consensus Estimate by 55.4%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Full-year 2024 EPS was $1.75, against the loss of 72 cents per share in the comparable 2023 period. The metric surpassed the Zacks Consensus Estimate by 31.6%.Inspire Medical registered revenues of $239.7 million in the fourth quarter, up 24.5% year over year. The figure beat the Zacks Consensus Estimate by 0.04%.Full-year 2024 revenues were $802.8 million, reflecting a 28.5% increase from the comparable 2023 period.During the reported quarter, Inspire Medical activated 72 new U.S. centers, thus bringing the total to 1,435 U.S. medical centers providing Inspire therapy. The company also created 12 new U.S. sales territories in the quarter, bringing the total to 335 U.S. sales territories.Inspire Medical Sy","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insp-stock-declines-despite-q4-162300939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RMD","CAH","RMD.AU","INSP","BSX"],"gpt_icon":0},{"id":"2510341331","title":"MYGN Stock Might Rise on Collaboration With CancerCARE","url":"https://stock-news.laohu8.com/highlight/detail?id=2510341331","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510341331?lang=en_us&edition=fundamental","pubTime":"2025-02-11 22:26","pubTimestamp":1739283960,"startTime":"0","endTime":"0","summary":"Myriad Genetics, Inc. MYGN recently announced an agreement to enhance education and access to hereditary cancer testing for CancerCARE for Life members.Under the agreement, more than 1 million individuals within CancerCARE’s network will be able to assess their eligibility for the MyRisk test by taking the MyGeneHistory quiz. If they meet the criteria, they will be directed to a clinician who can order the MyRisk with RiskScore Hereditary Cancer Test on their behalf.The latest collaboration is aimed at bolstering the company’s Hereditary Cancer testing business.Myriad Genetic’s shares lost 1.5% last Thursday.The company has been gaining synergies from its MyRisk Hereditary Cancer Test. In December 2024, the American Journal of Human Genetics named the MyRisk Hereditary Cancer Test with RiskScore study as one of the top 10 significant advances in genomic medicine.Moreover, MyRisk is expected to continue its strong growth from expanded guidelines and acceleration of EMR integrations. Acc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mygn-stock-might-rise-collaboration-142600747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","RMD.AU","BK4585","BK4548","BK4504","MYGN","BK4567","LU2177674079.SGD","BK4588","OMCL","LU2008162690.USD","VCYT","RMD","BK4139","BK4167"],"gpt_icon":0},{"id":"2510359515","title":"ResMed Close To Joining Very Elite Stock Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2510359515","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510359515?lang=en_us&edition=fundamental","pubTime":"2025-02-11 16:00","pubTimestamp":1739260800,"startTime":"0","endTime":"0","summary":"ResMed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.","market":"nz","thumbnail":"https://www.investors.com/wp-content/uploads/2019/01/stock-ResMed-01-shutter-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2019/01/stock-ResMed-01-shutter-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/resmed-getting-closer-to-key-technical-benchmark/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["IE00BFTCPJ56.SGD","LU2491049909.HKD","LU1291159041.SGD","LU0238689110.USD","LU1804176565.USD","IE00BJJMRZ35.SGD","BSX","LU2324357040.USD","LU1057294990.SGD","LU2242649171.HKD","BK7501","LU1153585028.USD","IE0002141913.USD","LU1989771016.USD","LU0823417653.USD","RS","BK4548","LU1983299246.USD","LU0267386448.USD","LU1989772923.USD","LU2491050154.USD","LU0882574055.USD","LU2491050071.SGD","BK4006","LU1989764748.USD","LU0823417737.USD","LU0048584097.USD","RMD.AU","LU0122379950.USD","BK4504","BSX.AU","LU0528227936.USD","LU0187121727.USD","LU2265009873.SGD","BK7007","LU2008162690.USD","IE00BJT1NW94.SGD","LU1791710582.SGD","LU2506951958.HKD","IE00B4R5TH58.HKD","LU2362540622.SGD","LU2506952170.USD","LU0345769631.USD","RMD","LU0251132253.USD","LU0950375773.USD","LU2362541273.HKD","LU2177674079.SGD","BK4588","BK4082"],"gpt_icon":1},{"id":"2510353067","title":"ResMed Getting Closer To Key Technical Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2510353067","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510353067?lang=en_us&edition=fundamental","pubTime":"2025-02-11 16:00","pubTimestamp":1739260800,"startTime":"0","endTime":"0","summary":"ResMed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating","market":"hk","thumbnail":"https://www.investors.com/wp-content/uploads/2017/05/IRU77-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/05/IRU77-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/ibd-data-stories/resmed-getting-closer-to-key-technical-benchmark/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4567","RMD.AU","RMD","BK4588","BK7007","BK7501","BK4548","LU2177674079.SGD","BK4082","BK4504","BK4585","BK4006","RS","LU2008162690.USD"],"gpt_icon":0},{"id":"2510814988","title":"Resmed Chief Financial Officer Sells 1,000 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2510814988","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510814988?lang=en_us&edition=fundamental","pubTime":"2025-02-11 07:32","pubTimestamp":1739230326,"startTime":"0","endTime":"0","summary":"Resmed  Chief Financial Officer Brett Sandercock sold 1,000 of his shares in the company on the New York Stock Exchange, with an aggregate market value of roughly $238,980, according to a Monday filing with the Australian bourse.Following the transaction, Brett now owns nearly 146.9 million shares and other units outstanding in the company, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2177674079.SGD","BK4504","BK7007","XJO.AU","BK4548","BK4567","RMD","XAO.AU","XKO.AU","LU2008162690.USD","RMD.AU","BK7501","BK4585","BK4082","BK4588"],"gpt_icon":0},{"id":"2510789512","title":"Avantor Stock Declines Despite Q4 Earnings Beat, Margins Expand","url":"https://stock-news.laohu8.com/highlight/detail?id=2510789512","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510789512?lang=en_us&edition=fundamental","pubTime":"2025-02-11 00:42","pubTimestamp":1739205720,"startTime":"0","endTime":"0","summary":"Avantor, Inc. AVTR reported fourth-quarter 2024 adjusted earnings per share  of 27 cents, up 8% from the year-ago quarter. The bottom line surpassed the Zacks Consensus Estimate by 8%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.GAAP EPS for the quarter was 73 cents, up from 15 cents year over year.Full-year 2024 EPS was 99 cents, reflecting a 6.6% decrease from the comparable 2023 period.Avantor's foreign currency translation and Clinical Services divestiture had an unfavorable impact in the reported quarter, resulting in an organic sales growth of 1%.Per management, Bioprocessing  exceeded expectations with high single-digit growth. Avantor also saw another strong quarter of order intake, with orders increasing meaningfully on a sequential basis. The silicones offering grew double digits, while electronic materials were stable sequentially with an expected year-over-year decline.Avantor exited 2024 with cash and cash equivalents of $261.9 million compared wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avantor-stock-declines-despite-q4-164200250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD.AU","CAH","RMD","AVTR"],"gpt_icon":0},{"id":"2510862818","title":"Why ResMed (RMD) is a Top Growth Stock for the Long-Term","url":"https://stock-news.laohu8.com/highlight/detail?id=2510862818","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510862818?lang=en_us&edition=fundamental","pubTime":"2025-02-10 22:45","pubTimestamp":1739198714,"startTime":"0","endTime":"0","summary":"Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.Why This 1 Growth Stock Should Be On Your Watchlist. Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time.ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-resmed-rmd-top-growth-144514941.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4588","BK4504","BK4548","LU2008162690.USD","LU2177674079.SGD","RMD","BK7501","BK7007","BK4082","RMD.AU","BK4567","BK4585"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RMD.AU\",params:#limit:5,,,undefined,":[{"date":"2025-05-07","symbol":"RMD.AU","amount":0.053,"announcedDate":"2025-04-24","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-05-08","defaultRemindTime":1746576000000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-12","payableDate":"2025-05-08","currency":"USD","dateTimestamp":1746540000000,"payDate":"2025-06-12"},{"date":"2025-02-12","symbol":"RMD.AU","amount":0.053,"announcedDate":"2025-01-31","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-02-13","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-20","payableDate":"2025-02-13","currency":"USD","dateTimestamp":1739278800000,"payDate":"2025-03-20"},{"date":"2024-11-06","symbol":"RMD.AU","amount":0.053,"announcedDate":"2024-10-25","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-11-07","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-12","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730811600000,"payDate":"2024-12-12"},{"date":"2024-08-14","symbol":"RMD.AU","amount":0.053,"announcedDate":"2024-08-02","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-08-15","defaultRemindTime":1723593600000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-19","payableDate":"2024-08-15","currency":"USD","dateTimestamp":1723557600000,"payDate":"2024-09-19"},{"date":"2024-05-08","symbol":"RMD.AU","amount":0.048,"announcedDate":"2024-04-26","type":"dividend","market":"AU","newRecordDate":"2024-05-09","defaultRemindTime":1715126400000,"name":"Resmed DRC","recordDate":"2024-06-13","payableDate":"2024-05-09","currency":"USD","dateTimestamp":1715090400000,"payDate":"2024-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RMD.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-08-19","recordDate":"2020-08-20","paymentDate":"2020-09-24","value":0.039,"currency":"USD"},{"executeDate":"2020-11-11","recordDate":"2020-11-12","paymentDate":"2020-12-17","value":0.039,"currency":"USD"},{"executeDate":"2021-02-10","recordDate":"2021-02-11","paymentDate":"2021-03-18","value":0.039,"currency":"USD"},{"executeDate":"2021-05-12","recordDate":"2021-05-13","paymentDate":"2021-06-17","value":0.039,"currency":"USD"},{"executeDate":"2021-08-18","recordDate":"2021-08-19","paymentDate":"2021-09-23","value":0.042,"currency":"USD"}]}}